AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Significant Growth in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 7,013,343 shares, an increase of 5,016.3% from the May 14th total of 137,078 shares. Based on an average daily trading volume, of 123,199,850 shares, the short-interest ratio is currently 0.1 days. Approximately 48.2% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets cut their target price on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $9.00.

AIM ImmunoTech Stock Down 22.3%

NYSEAMERICAN:AIM traded down $0.12 on Tuesday, hitting $0.40. The stock had a trading volume of 10,626,895 shares, compared to its average volume of 17,777,662. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.01 and a current ratio of 1.01. The stock has a market cap of $5.87 million, a P/E ratio of -0.06 and a beta of 1.18. AIM ImmunoTech has a 1 year low of $0.21 and a 1 year high of $20.35. The firm’s fifty day simple moving average is $0.49 and its two-hundred day simple moving average is $0.92.

AIM ImmunoTech (NYSEAMERICAN:AIM) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.69) EPS for the quarter. The business had revenue of $0.02 million for the quarter. Analysts predict that AIM ImmunoTech will post -0.63 earnings per share for the current year.

Institutional Investors Weigh In On AIM ImmunoTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in AIM. Sabby Management LLC purchased a new stake in AIM ImmunoTech during the third quarter worth about $79,000. DRW Securities LLC increased its holdings in AIM ImmunoTech by 60.6% during the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after buying an additional 26,254 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in AIM ImmunoTech during the second quarter worth about $87,000. Hedge funds and other institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.